Bottom line
MRAGX vs SCHG: the short answer
MRAGX (Meridian Growth Fund) and SCHG (Schwab U.S. Large-Cap Growth ETF) are both mutual funds.
But SCHG is far broader, holding 197 positions to 91 for MRAGX, so beyond the top names it adds exposure MRAGX doesn't have.
SCHG is cheaper at 0.04% vs 1.29% — a difference of $125 a year per $10,000 invested.
Over five years, SCHG returned +19.7% a year vs −2.7% for MRAGX (reporting dates differ).
MRAGX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
MRAGX vs SCHG side by side
| MRAGX | SCHG | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Meridian | Schwab |
| Category | Large Growth | Large Growth |
| Expense ratio | 1.29% | 0.04% |
| Annual cost per $10k | $129 | $4 |
| 10-yr cost on $10k (prospectus) | $2,042 | $51 |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | — |
| 1-yr return | −11.9% | +34.9% |
| 5-yr return (annualized) | −2.7% | +19.7% |
| 10-yr return (annualized) | +6.4% | +16.7% |
| Best quarter | — | +27.7% |
| Worst quarter | — | −22.3% |
| Net assets (fund) | $542.9M | $61.1B |
| Number of holdings | 91 | 197 |
| Portfolio turnover | 49% | 27% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
MRAGX and SCHG share none of their top holdings.
MRAGX top 10
- Stit Govt And Agency Inst — 4.17%
- Rb Global Inc — 2.49%
- Curtiss-wright Corp — 2.46%
- Axogen Inc — 2.43%
- Federal Signal Corp — 2.36%
- Hinge Health Inc — 2.29%
- Definium Therapeutics Inc — 2.20%
- Veracyte Inc — 2.14%
- Standardaero Inc — 2.09%
- Turning Point Brands Inc — 2.08%
SCHG top 10
- NVIDIA Corp — 11.01%
- Apple Inc — 9.83%
- Microsoft Corp — 7.17%
- Amazon.com Inc — 5.67%
- Alphabet Inc — 4.75%
- Broadcom Inc — 4.55%
- Tesla Inc — 3.91%
- Alphabet Inc — 3.78%
- Meta Platforms Inc — 3.45%
- Eli Lilly & Co — 3.05%
FAQ
What is the difference between MRAGX and SCHG?
Which is cheaper, MRAGX or SCHG?
Should I own both MRAGX and SCHG?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.